Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipiracil/trifluridine - Taiho Pharmaceutical

Next Previous
X
Search
Drug Profile

Tipiracil/trifluridine - Taiho Pharmaceutical

Alternative Names: FTD/TPI; Lonsurf; Orcantas; S 95005; S 95005/TAS-102; T15, T20; T15/T20; TAS-102; TAS-102/S-95005; Tipiracil-hydrochloride/trifluridine; Trifluridine/tipiracil; Trifluridine/tipiracil hydrochloride

Latest Information Update: 20 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Amgen; Baylor Research Institute; Emory University; Ipsen; Servier; Taiho Oncology; Taiho Pharmaceutical; TTY Biopharm; University of Florida; University of Wisconsin-Madison
  • Class Antineoplastics; Nucleosides; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer
  • Phase II Bladder cancer; Cholangiocarcinoma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Squamous cell cancer
  • Phase I/II Gastrointestinal cancer
  • No development reported Solid tumours

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase Ib/II trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Taiho Pharmaceutical terminates phase I/II trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Australia due to slow recruitment (PO) (ACTRN12617001190392)
  • 17 May 2024 Taiho in collaboration with M.D. Anderson Cancer Center terminates a phase II trial for Colorectal cancer in USA (NCT05343013)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top